{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T21:10:00Z","timestamp":1754601000865,"version":"3.38.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clgc.2025.102308","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T09:03:10Z","timestamp":1738227790000},"page":"102308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidence of Significant Prostate Cancer in the Follow-Up of Patients With Suspicious Lesion on MRI and Negative Targeted and systematic Biopsies"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9441-0640","authenticated-orcid":false,"given":"Claire","family":"Siebert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Truong-An","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Fourcade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Zambon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Saout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Deruelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Joulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Doucet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Valeri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clgc.2025.102308_bib0001","first-page":"503\u201111","article-title":"Predictive clinical features for negative histopathology of MRI\/ultrasound-fusion-guided prostate biopsy in patients with high likelihood of cancer at prostate MRI: analysis from a urologic outpatient clinic1","volume":"76","author":"Apfelbeck","year":"2020","journal-title":"Clin Hemorheol Microcirc"},{"issue":"2","key":"10.1016\/j.clgc.2025.102308_bib0002","doi-asserted-by":"crossref","first-page":"235\u201141","DOI":"10.1007\/s00345-018-2337-0","article-title":"Follow-up of negative MRI-targeted prostate biopsies: when are we missing cancer?","volume":"37","author":"Gold","year":"2019","journal-title":"World J Urol"},{"issue":"15","key":"10.1016\/j.clgc.2025.102308_bib0003","first-page":"1275\u2011372","article-title":"French AFU Cancer Committee guidelines - update 2022-2024: prostate cancer - diagnosis and management of localised disease","volume":"32","author":"Ploussard","year":"2022","journal-title":"Progres En Urol J Assoc Francaise Urol Soc Francaise Urol"},{"issue":"12","key":"10.1016\/j.clgc.2025.102308_bib0004","doi-asserted-by":"crossref","first-page":"1750\u20114","DOI":"10.1111\/j.1464-410X.2011.10809.x","article-title":"Optimising repeat prostate biopsy decisions and procedures","volume":"109","author":"Kirby","year":"2012","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.clgc.2025.102308_bib0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.urolonc.2021.09.015","article-title":"How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series","volume":"40","author":"Barletta","year":"2022","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102308_bib0006","doi-asserted-by":"crossref","first-page":"748\u201154","DOI":"10.1097\/JU.0000000000001424","article-title":"Followup of men with PI-RADSTM 4 or 5 abnormality on prostate Magnetic resonance imaging and nonmalignant pathological findings on initial targeted prostate biopsy","volume":"205","author":"Meng","year":"2021","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102308_bib0007","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.clgc.2025.102308_bib0008","doi-asserted-by":"crossref","first-page":"452\u20117","DOI":"10.1016\/j.eururo.2022.07.025","article-title":"Prostate cancer detection percentages of repeat biopsy in patients with positive multiparametric magnetic resonance imaging (Prostate Imaging Reporting and Data System\/Likert 3-5) and negative initial biopsy. A mini systematic review","volume":"82","author":"Grivas","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102308_bib0009","first-page":"897\u2011901","article-title":"Early second round targeted biopsy of PI-RADS score 3 or 4 in 256 men with persistent suspicion of prostate cancer","volume":"33","author":"Pepe","year":"2019","journal-title":"Vivo Athens Greece"},{"issue":"2","key":"10.1016\/j.clgc.2025.102308_bib0010","doi-asserted-by":"crossref","first-page":"463\u20119","DOI":"10.1007\/s00345-022-04243-5","article-title":"Investigating PSMA-PET\/CT to resolve prostate MRI PIRADS4-5 and negative biopsy discordance","volume":"41","author":"Wong","year":"2023","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2025.102308_bib0011","article-title":"Negative biopsy histology in men with PI-RADS score 5: is it useful PSMA PET\/CT evaluation?","volume":"96","author":"Pepe","year":"2024","journal-title":"Arch Ital Urol E Androl"},{"issue":"1","key":"10.1016\/j.clgc.2025.102308_bib0012","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.clgc.2016.07.007","article-title":"Transperineal versus transrectal MRI\/TRUS fusion targeted biopsy: detection rate of clinically significant prostate cancer","volume":"15","author":"Pepe","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2025.102308_bib0013","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000501527","article-title":"Cancer Location in Upgrading and Detection after Transperineal Template-Guided Mapping Biopsy for Patients in Active Surveillance and Negative Transrectal Ultrasonography-Guided Prostate Biopsy","volume":"103","author":"Lee","year":"2019","journal-title":"Urol Int"},{"issue":"6","key":"10.1016\/j.clgc.2025.102308_bib0014","first-page":"621\u20118","article-title":"Is there an impact of transperineal versus transrectal Magnetic resonance imaging-targeted biopsy in clinically significant prostate cancer detection rate? A systematic review and meta-analysis","volume":"6","author":"Uleri","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102308_bib0015","first-page":"904\u201113","article-title":"Magnetic resonance imaging\/ultrasound fusion-guided transperineal versus Magnetic resonance imaging\/ultrasound fusion-guided transrectal prostate biopsy-a systematic review","volume":"4","author":"Rai","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102308_bib0016","doi-asserted-by":"crossref","first-page":"288\u201196","DOI":"10.1038\/pcan.2015.29","article-title":"Improved detection of anterior fibromuscular stroma and transition zone prostate cancer using biparametric and multiparametric MRI with MRI-targeted biopsy and MRI-US fusion guidance","volume":"18","author":"Radtke","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.clgc.2025.102308_bib0017","doi-asserted-by":"crossref","first-page":"616\u201124","DOI":"10.23736\/S2724-6051.20.04008-4","article-title":"Fusion US\/MRI prostate biopsy using a computer aided diagnostic (CAD) system","volume":"73","author":"Ferriero","year":"2021","journal-title":"Minerva Urol Nephrol"},{"issue":"24","key":"10.1016\/j.clgc.2025.102308_bib0018","article-title":"A systematic review of the diagnostic accuracy of deep learning models for the automatic detection, localization, and characterization of clinically significant prostate cancer on magnetic resonance imaging","volume":"S2588-9311","author":"Moli\u00e8re","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2025.102308_bib0019","doi-asserted-by":"crossref","first-page":"e244\u201152","DOI":"10.1016\/j.clgc.2022.01.015","article-title":"Impact of multiparametric MRI and PSA density on the initial indication or the maintaining in active surveillance during follow-up in low-risk prostate cancer","volume":"20","author":"Saout","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"10.1016\/j.clgc.2025.102308_bib0020","first-page":"1031\u20117","article-title":"Combination of biparametric magnetic resonance imaging with prostate-specific antigen density to stratify the risk of significant prostate cancer: initial biopsy and long-term follow-up results","volume":"29","author":"Konishi","year":"2022","journal-title":"Int J Urol Off J Jpn Urol Assoc"},{"issue":"2","key":"10.1016\/j.clgc.2025.102308_bib0021","first-page":"139\u201142","article-title":"mpMRI PI-RADS score 3 lesions diagnosed by reference vs affiliated radiological centers: our experience in 950 cases","volume":"93","author":"Pepe","year":"2021","journal-title":"Arch Ital Urol E Androl"},{"issue":"6","key":"10.1016\/j.clgc.2025.102308_bib0022","doi-asserted-by":"crossref","first-page":"e698\u2011704","DOI":"10.1016\/j.clgc.2020.04.006","article-title":"The use of multiparametric Magnetic resonance imaging for follow-up of patients included in active surveillance protocol. Can PSA density discriminate patients at different risk of reclassification?","volume":"18","author":"Roscigno","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"10.1016\/j.clgc.2025.102308_bib0023","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.urolonc.2023.05.005","article-title":"Optimal PSA density threshold and predictive factors for the detection of clinically significant prostate cancer in patient with a PI-RADS 3 lesion on MRI","volume":"41","author":"Nguyen","year":"2023","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2025.102308_bib0024","doi-asserted-by":"crossref","first-page":"13603","DOI":"10.1038\/s41598-022-17260-6","article-title":"Follow-up of men with a PI-RADS 4\/5 lesion after negative MRI\/ultrasound fusion biopsy","volume":"12","author":"Kornienko","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.clgc.2025.102308_bib0025","doi-asserted-by":"crossref","first-page":"e684\u20117","DOI":"10.1016\/j.clgc.2020.04.001","article-title":"Negative biopsy histology in men with PI-RADS score 5 in daily clinical practice: incidence of granulomatous prostatitis","volume":"18","author":"Pepe","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"10.1016\/j.clgc.2025.102308_bib0026","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.urolonc.2022.06.011","article-title":"Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?","volume":"40","author":"Castellani","year":"2022","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2025.102308_bib0027","doi-asserted-by":"crossref","first-page":"1180\u20116","DOI":"10.1097\/JU.0000000000001232","article-title":"Risk of prostate cancer after a negative magnetic resonance imaging guided biopsy","volume":"204","author":"Kinnaird","year":"2020","journal-title":"J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:36:50Z","timestamp":1741696610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1558767325000102"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102308","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of Significant Prostate Cancer in the Follow-Up of Patients With Suspicious Lesion on MRI and Negative Targeted and systematic Biopsies","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102308"}}